Launching three new biosimilar products and its toripalimab novel immuno-oncology product in the next 15 months is expected to deliver revenues of at least $1.2bn by 2026, Coherus BioSciences, Inc. has disclosed as part of the company’s landmark first annual analyst day.
They could however reach as high as $2.2bn by that point, chief financial officer McDavid Stillwell told attendees. The company’s...






